Related articles
Eli Lilly
U.S. rival of Novo Nordisk in the obesity drug market; markets Foundayo and develops retatrutide.
- Novo Nordisk Raises 2026 Outlook for Third Time
- Biograil raises €20 million to advance oral alternative to injectable drugs
- Novo raises full-year outlook after strong Wegovy pill sales
- Drugmakers face scrutiny over Russian intermediaries as Dupixent rival data nears
- Wegovy Pill Arrives in French Pharmacies as Obesity Drug Competition Heats Up